Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

rheumatic fever/feber

Länken sparas på Urklipp
9 resultat

Test for rheumatic fever and monoclonal antibodies useful therefor

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION This invention is concerned with monoclonal antibodies useful to detect humans who are susceptible to attacks of rheumatic fever. It is concerned also with methods of producing and using such antibodies, compositions containing them, hybridoma cell lines useful for

Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This application is a National Stage Application of International Application Number PCT/EP2007/004898, filed Jun. 1, 2007; which claims priority to European Patent Application No. 06011685.2, filed Jun. 6, 2006, all of which are incorporated herein in their entirety. The present invention relates

Compound WS 727713

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD The present invention relates to a new compound which is useful as a medicament or a cosmetic, to a process for producing the same and to a pharmaceutical composition comprising the same. BACKGROUND ART The melanocortin (MC) is a group of peptide hormones that are derived from

Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION This invention relates to compounds and pharmaceutical compositions for the treatment of cyclooxygenase mediated diseases and methods of treating thereof. Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a 371 of PCT/KR2010/007845, filed Nov. 8, 2010, which claims the benefit of Korean Patent Application No. 10-2009-0106912, filed Nov. 6, 2009, the entire contents of each of which are incorporated herein by reference. TECHNICAL FIELD The

Vaccine against group A beta hemolytic streptococcus and respective process for obtaining thereof

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The Applicant already holds patent application PI 0501290-2, filed on Mar. 24, 2005, referring to a "VACCINE AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF". This patent refers to a new vaccine whose purpose is the same, as well as a

Antigen of hybrid M protein and carrier for group A streptococcal vaccine

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION The present invention relates broadly to the field of recombinant vaccines. The vaccines are directed to preventing Group A streptococcal infections, which may otherwise result in rheumatic fever. BACKGROUND OF THE INVENTION Acute rheumatic fever (ARF) is the major cause of heart

Antigen of hybrid M protein and carrier for Group A streptococccal vaccine

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION The present invention relates broadly to the field of recombinant vaccines. The vaccines are directed to preventing Group A streptococcal infections, which may otherwise result in rheumatic fever. BACKGROUND OF THE INVENTION Acute rheumatic fever (ARF) is the major cause of heart

Recombinant multivalent M protein vaccine

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The invention relates to recombinant multivalent M protein vaccines useful to control group A streptococcal infections of different serotypes which may result in rheumatic fever, rheumatic heart disease, and to other embodiments further described herein. BACKGROUND OF THE
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge